Breaking News

Parkinson’s study will look at Ashkenazi Jewish genetic mutation

(JTA) — A study sponsored by The Michael J. Fox Foundation for Parkinson’s Research will investigate a genetic mutation found more often in Ashkenazi Jews.

The Parkinson’s Progression Markers Initiative, a large-scale biomarker study, is expanding to study individuals with genetic mutations associated with Parkinson’s disease.

Among those mutations is the LRRK2, which accounts for a greater number of Parkinson’s cases among certain ethnic populations and families, notably Jews of Eastern European descent.

The study will enroll 250 people with the LRRK2 mutation and Parkinson’s and a like number with the mutation but without Parkinson’s.

Genetic mutations account for 5 percent to 10 percent of all Parkinson’s cases, but a study of these individuals may reveal disease traits that apply to all Parkinson’s patients.

The Fox Foundation has secured 15 industry partners and co-funding sponsors for the initiative. They include Abbott Laboratories, Biogen, BMS, Covance, Eli Lilly, GE Healthcare, Genentech, GSK, Merck, Pfizer and Roche.

The study will take place at 32 clinical sites around the world.

…read more
Source: JTA

Please ShareShare on FacebookTweet about this on TwitterShare on Google+Share on LinkedInShare on StumbleUponPin on PinterestEmail this to someone

Jewish Content

Posted by on February 26, 2014. Filed under Jewish News. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.